Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||1.59%||182.51||0.7%||$1411.48m|
|MRK||Merck & Co., Inc.||1.39%||93.28||0.7%||$1241.52m|
|BMY||Bristol-Myers Squibb Co.||1.67%||78.99||1.0%||$1137.41m|
|LLY||Eli Lilly & Co.||4.15%||325.69||1.1%||$1136.04m|
|TPTX||Turning Point Therapeutics, Inc.||0.03%||75.17||0.0%||$291.93m|
|SIGA||SIGA Technologies, Inc.||-0.46%||13.04||0.0%||$219.68m|
|MRTX||Mirati Therapeutics, Inc.||3.45%||68.16||1.6%||$199.41m|
|HZNP||Horizon Therapeutics Plc||2.68%||85.13||5.4%||$182.59m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||-0.14%||144.00||0.0%||$147.86m|
Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Salt Lake City, UT.